On Tuesday, November 13, we hosted our Meet the Mesothelioma Experts live broadcast with Dr. Marjorie Zauderer, of Memorial Sloan Kettering Cancer Center and chair of our board of directors, and Dr. John Bomalaski, of Polaris Pharmaceuticals. Dr. Zauderer and Dr. Bomalaski discussed the ATOMIC-Meso Phase 2/3 Study, a front-line clinical trial for non-epithelioid mesothelioma, and answered registrants’ questions in real time.
Study Summary:
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma has been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
A recording of the session is available on our website.
As part of the Meet the Mesothelioma Experts series, the Meso Foundation invites specialists in the field of mesothelioma to discuss their current research interests as well as promising developments in the treatment of mesothelioma. You can listen to audio files of past sessions on our website. If you wish to receive emails from the Meso Foundation, including alerts about new installments of the Meet the Mesothelioma Experts series, please sign up for our news on the right side of your screen.
